Aankondiging • Dec 05
Tissue Regenix Group plc announced that it expects to receive £17.5 million in funding from Harwood Private Equity VI L.P. Tissue Regenix Group plc announced a private placement to issue Secured Convertible Loan Notes for the proceeds of £17.5 million on December 4, 2025. The transaction involves participation of Harwood Private Equity VI L.P. Of the Secured Convertible Loan Notes (the "Secured Convertible Loan Notes" or "Notes"), £7.5 million will be issued immediately on the passing of the necessary Resolutions at a general meeting to be held by the Company, and a further £10.0 million will then be available to the Company for drawdown. The conversion price is £0.001. The general meeting, to seek shareholder approval of the Resolutions, will be held on December 22, 2025. Transaction is expected to close on December 22, 2025. Board Change • Oct 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Brian Phillips was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Oct 19
Tissue Regenix Appoints Kirsten Lund to Board, Effective October 16, 2025 Tissue Regenix Group plc announced on 16 October 2025, Kirsten Lund, CFO, has joined the board with immediate effect. New Risk • Oct 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.19m (US$9.70m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.5m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Market cap is less than US$10m (UK£7.19m market cap, or US$9.70m). Reported Earnings • Sep 30
First half 2025 earnings released: US$0.013 loss per share (vs US$0.004 loss in 1H 2024) First half 2025 results: US$0.013 loss per share (further deteriorated from US$0.004 loss in 1H 2024). Revenue: US$13.8m (down 16% from 1H 2024). Net loss: US$957.0k (loss widened 241% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Aankondiging • Sep 09
Tissue Regenix Group plc to Report First Half, 2025 Results on Sep 18, 2025 Tissue Regenix Group plc announced that they will report first half, 2025 results on Sep 18, 2025 New Risk • Sep 08
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$5.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (UK£21.4m market cap, or US$28.9m). Aankondiging • Aug 01
Tissue Regenix Group plc Announces Chief Financial Officer Changes, Effective August 1, 2025 Tissue Regenix Group plc announced that following initial notification at the final results for the year ended December 31, 2024, David Cocke will retire on August 1, 2025 from his role as Chief Financial Officer ('CFO'). Brandon Largent, Associate Vice President of Finance at Tissue Regenix will replace David in a non-board role as Interim CFO with immediate effect. Brandon has over 25 years' experience leading financial operations across PE-backed, private and publicly listed companies. Prior to his role as Associate Vice President of Finance at Tissue Regenix, Brandon was Financial Planning & Analysis Manager (Commercial Division) for Groundworks, a provider of patented groundwork solutions, leading a post-acquisition finance transformation and post-merger integration for Groundworks' entry into the commercial sector. Brandon has also held positions as CFO of Merlin One Aircraft, an USD 8 Million private charter aviation firm and as Finance Manager (US Operations) at Tissue Regenix from 2020-2022. New Risk • Jul 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$5.7m). Currently unprofitable and not forecast to become profitable over next 2 years (US$191k net loss in 2 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£20.7m market cap, or US$27.9m). Aankondiging • Jun 28
Tissue Regenix Group plc, Annual General Meeting, Jul 23, 2025 Tissue Regenix Group plc, Annual General Meeting, Jul 23, 2025. Location: dla piper uk llp, city square house, 11 wellington st, leeds, ls1 4dl, United Kingdom Reported Earnings • Jun 26
Full year 2024 earnings released: US$0.012 loss per share (vs US$0.024 loss in FY 2023) Full year 2024 results: US$0.012 loss per share (improved from US$0.024 loss in FY 2023). Revenue: US$28.6m (down 2.9% from FY 2023). Net loss: US$885.0k (loss narrowed 48% from FY 2023). Revenue is forecast to grow 7.1% p.a. on average during the next 2 years, compared to a 9.2% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£26.2m market cap, or US$33.9m). Aankondiging • Jul 16
Tissue Regenix Group plc to Report First Half, 2024 Results on Sep 10, 2024 Tissue Regenix Group plc announced that they will report first half, 2024 results on Sep 10, 2024 Major Estimate Revision • Apr 12
Consensus EPS estimates fall from profit to US$0.0021 loss The consensus outlook for fiscal year 2024 has been updated. Expected to report loss instead of -US$0.0021 instead of US$0.00 per share profit previously forecast. Revenue forecast unchanged at US$34.0m Biotechs industry in the United Kingdom expected to see average net income growth of 4.0% next year. Consensus price target of UK£1.20 unchanged from last update. Share price was steady at UK£0.61 over the past week. Reported Earnings • Mar 20
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: US$0.024 loss per share (improved from US$0.038 loss in FY 2022). Revenue: US$29.5m (up 21% from FY 2022). Net loss: US$1.71m (loss narrowed 36% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Aankondiging • Mar 20
Tissue Regenix Group plc, Annual General Meeting, Apr 25, 2024 Tissue Regenix Group plc, Annual General Meeting, Apr 25, 2024, at 10:00 Coordinated Universal Time. Location: DLA Piper, 160 Aldersgate St, Barbican - London United Kingdom Breakeven Date Change • Mar 19
Forecast breakeven date pushed back to 2025 The analyst covering Tissue Regenix Group previously expected the company to break even in 2024. New forecast suggests the company will make a profit of US$398.6k in 2025. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Aankondiging • Mar 01
Tissue Regenix Group plc to Report Fiscal Year 2023 Results on Mar 19, 2024 Tissue Regenix Group plc announced that they will report fiscal year 2023 results on Mar 19, 2024 Reported Earnings • Sep 07
First half 2023 earnings released: US$0.013 loss per share (vs US$0.023 loss in 1H 2022) First half 2023 results: US$0.013 loss per share (improved from US$0.023 loss in 1H 2022). Revenue: US$14.1m (up 19% from 1H 2022). Net loss: US$893.0k (loss narrowed 44% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Aankondiging • Sep 05
Tissue Regenix Group plc Announces the Launch of its New BioRinse® Product Line for All Sports Medicine Allografts Tissue Regenix Group plc announced the launch of its new BioRinse® product line for all sports medicine allografts that Tissue Regenix distributes in the US and internationally. The Company's BioRinse sterilisation technology platform uses proprietary processes to produce sterile bone and soft tissue products. The new process for sports medicine allografts causes less damage to the tissue in order to produce an enhanced sterile soft tissue product. The primary market for these grafts is sports medicine, mainly consisting of tendon and ligament reconstruction procedures in the knee, ankle, elbow, and other joints. The Company has previously discussed plans to innovate the processing protocols for its soft tissue products in order to enhance performance, efficiency, and safety in the products that Tissue Regenix already produces for the sports medicine market. These changes will allow Tissue Regenix to capture a larger segment of the estimated USD 300 million market for allograft soft tissue tendons for ligament reconstruction procedures of the knee. New Risk • Sep 05
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$2.7m Forecast net loss in 1 year: US$564k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$564k net loss next year). Market cap is less than US$100m (UK£37.7m market cap, or US$47.4m). Major Estimate Revision • Apr 06
Consensus EPS estimates fall from profit to US$0.0001 loss The consensus outlook for fiscal year 2023 has been updated. Expected to report loss instead of -US$0.0001 instead of US$0.00 per share profit previously forecast. Revenue forecast unchanged at US$29.2m Biotechs industry in the United Kingdom expected to see average net income decline 11% next year. Consensus price target of UK£0.012 unchanged from last update. Share price fell 2.6% to UK£0.0056 over the past week. Major Estimate Revision • Mar 28
Consensus EPS estimates increase from loss to US$0.00 profit, revenue downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$30.6m to US$28.8m. EPS estimate of -US$0.0001 up from expected loss of US$0.00 per share previously. Biotechs industry in the United Kingdom expected to see average net income decline 12% next year. Consensus price target of UK£0.012 unchanged from last update. Share price fell 9.9% to UK£0.0054 over the past week. Reported Earnings • Mar 21
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: US$0 (improved from US$0.001 loss in FY 2021). Revenue: US$24.5m (up 24% from FY 2021). Net loss: US$2.70m (loss narrowed 44% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Aankondiging • Dec 07
Tissue Regenix Group plc Launches VNEW® Fascia Lata Allograft, an Additional Line Extension to the Company's dCELL® Division Tissue Regenix Group plc announced the launch of VNEW® Fascia Lata allograft, an additional line extension to the Company's dCELL® division. The VNEW® Fascia Lata is a soft tissue allograft used to support weakened tissue that can result in stress urinary incontinence ('SUI'), which affects around one-third of adult women at some point in their lives1. The number of women undergoing surgery annually in the US for SUI is around 260,0002. The VNEW® Fascia Lata allograft is manufactured under an exclusive arrangement for ARMS Medical ('ARMS'), a partner with which Tissue Regenix entered into a multi-year exclusive distribution agreement (the 'Agreement') in 2018. The VNEW® brand is owned by ARMS and consists of uniquely shaped products that address pelvic health needs. The expansion of this Agreement with ARMS adds VNEW® Fascia Lata to the exclusive distribution portfolio of DermaPure® products to hospitals and surgeons throughout the US for use in urology and gynaecology procedures. Price Target Changed • Nov 16
Price target increased to UK£0.012 Up from UK£0.009, the current price target is provided by 1 analyst. New target price is 94% above last closing price of UK£0.0062. Stock is up 3.3% over the past year. The company is forecast to post a net loss per share of US$0.0004 next year compared to a net loss per share of US$0.00068 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Brian Phillips was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 07
First half 2022 earnings released: EPS: US$0 (vs US$0 in 1H 2021) First half 2022 results: EPS: US$0 (in line with 1H 2021). Revenue: US$11.8m (up 26% from 1H 2021). Net loss: US$1.60m (loss narrowed 30% from 1H 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Aankondiging • Jul 20
Tissue Regenix Group plc to Report Q2, 2022 Results on Sep 07, 2022 Tissue Regenix Group plc announced that they will report Q2, 2022 results on Sep 07, 2022 Aankondiging • Jul 19
Tissue Regenix Group plc Provides Revenue Guidance for Six Months Ended 30 June 2022 Tissue Regenix Group plc provided revenue guidance for six months ended 30 June 2022. Foe the period, the Group reports that trading in the first half of 2022 continues to be strong and in line with the Board's expectations, as healthcare markets in the United States begin the return to pre-pandemic levels. Group revenues for the Period are expected to be approximately $11.8 million, a 25% increase (27% in constant currency) on the prior year. The Board remains confident that the Group is on track to meet its expectations for the full year. Breakeven Date Change • Apr 27
Forecast breakeven date pushed back to 2024 The 2 analysts covering Tissue Regenix Group previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 73% per year to 2023. The company is expected to make a profit of US$2.37m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Brian Phillips was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Apr 20
Forecast breakeven date pushed back to 2024 The 2 analysts covering Tissue Regenix Group previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 73% per year to 2023. The company is expected to make a profit of US$2.37m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule. Reported Earnings • Mar 15
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: US$0.001 loss per share (up from US$0.003 loss in FY 2020). Revenue: US$19.7m (up 13% from FY 2020). Net loss: US$4.79m (loss narrowed 64% from FY 2020). Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 80%. Over the next year, revenue is forecast to grow 27%, compared to a 20% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Aankondiging • Mar 03
Tissue Regenix Group plc to Report Fiscal Year 2021 Results on Mar 15, 2022 Tissue Regenix Group plc announced that they will report fiscal year 2021 results on Mar 15, 2022 Recent Insider Transactions • Sep 26
Independent Non-Executive Director recently bought UK£55k worth of stock On the 23rd of September, Brian Phillips bought around 9m shares on-market at roughly UK£0.0061 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£123k more in shares than they have sold in the last 12 months. Reported Earnings • Apr 30
Full year 2020 earnings released: UK£0.002 loss per share (vs UK£0.006 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: UK£12.8m (down 1.6% from FY 2019). Net loss: UK£9.71m (loss widened 39% from FY 2019). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Aankondiging • Mar 19
Tissue Regenix Group plc Announces Completion of Initial Phase of US Facility Expansion Complete Tissue Regenix Group plc announced the completion of the initial phase of its expansion plan at the Company's San Antonio Texas facility. As previously disclosed, the Company had secured a ten-year lease on a 21,000 sq. ft facility adjacent to its existing facility to address manufacturing capacity constraints. The initial part of Phase one of the expansion project, which has now been completed, comprised of relocating facilities designated for distribution and frozen tissue storage, both of which had outgrown their existing space in the San Antonio facility. The new freezer facility triples the Company's current storage capacity allowing Tissue Regenix to hold more donor tissue onsite. The new distribution area enables the Company to integrate distribution and finished goods into a more efficient operating space. Work has also started on the development of two additional clean rooms at the existing San Antonio facility, which will bring the total number of clean rooms to seven, as well as the expansion space for supporting departments. These developments, which will complete Phase one of the expansion project, are scheduled for completion during first half of 2021. Aankondiging • Feb 26
Tissue Regenix Group plc Appoints Jonathan Glenn as Non-Executive Chairman Tissue Regenix Group plc announced that the Board has appointed Jonathan Glenn, current Interim Non-Executive Chairman, to the position of Non-Executive Chairman with immediate effect. Jonathan joined the Group in January 2016, and was appointed Interim Non-Executive Chairman in March 2020. Aankondiging • Jan 06
Tissue Regenix Group Announces Appointment of Brian Phillips and Trevor Phillips to the Board Tissue Regenix Group announced that, following the Group's announcement on 4 December 2020, Brian Phillips and Trevor Phillips have been appointed to the Board as independent Non-Executive Directors of Tissue Regenix. Brian Phillips is now Chair of the Audit Committee and Trevor Phillips is Chair of the Remuneration Committee. Aankondiging • Dec 06
Tissue Regenix Group plc Announces Board and Committee Changes Tissue Regenix Group announced its intention to appoint Brian Phillips and Trevor Phillips (no relation) as independent Non-Executive Directors of Tissue Regenix.Brian Phillips is an entrepreneurial investment professional with over 25 years' experience. Brian is the current Principal of Ethos partners which he co-founded in 2018 to assist individuals in establishing a portfolio of assets under private equity investments. Prior to this, Brian was Chief Investment Officer at Greenhill Capital Partners Europe LLP where he was responsible for setting up their UK business (2006-2010) and Managing Director of LGV Capital (2000-2006). Brian holds a B.Acc from Glasgow University and qualified as a Chartered Accountant with KMPG. Trevor Phillips is the current Chairman of the Board at NEPeSMO and has extensive experience in the UK and United States in corporate development, M&A and operations in the pharmaceutical and life science industries. Both Brian and Trevor will be appointed to the board of Tissue Regenix following the completion of the necessary regulatory due diligence in accordance with the AIM Rules. Following appointment, Brian Phillips will Chair the Audit Committee and Trevor Phillips will Chair the Renumeration Committee. Alongside this, after many years of service, Alan Miller and Randeep Grewal have notified the Board of their resignation as Non-Executive Directors with immediate effect. Aankondiging • Dec 04
Tissue Regenix Group plc Announces First Delivery of OrthoPure® XT Tissue Regenix Group plc announced that its first delivery of OrthoPure® XT has taken place with additional shipments expected in early 2021. OrthoPure® XT is a decellularized porcine tendon, developed using the Group's patented dCELL® technology. It was granted CE Mark approval in June 2020 for the reconstruction of knee ligaments to restore function and stability. In August 2020, the Company announced its first distribution agreement, focused on the UK market, with a speciality supplier of orthopedic and biologic products. The Group has since targeted key European markets including securing an additional distribution partner in Poland. The Group is currently engaged in a number of discussions with potential partners in other geographies. Aankondiging • Nov 18
Tissue Regenix Group plc Announces Executive Changes Tissue Regenix Group plc announced that it has appointed Daniel Lee as Chief Executive Officer. Danny joined the Group as President of U.S. Operations in January 2019. Danny will commence his new role and join the Board with immediate effect. He has nearly 30 years' experience in the medical device and biologics industry. Prior to joining the Group in January 2019, Danny was the Chief Executive Officer for Scaffold Biologics and Aperion Biologics. His previous senior management roles included global marketing for OsteoBiologics (acquired by Smith & Nephew Endoscopy in 1996) and marketing activities for Regeneration Technologies. Danny will succeed Gareth Jones, who joined the Company in October 2018 as Chief Financial Officer and was subsequently appointed Interim Chief Executive Officer in August 2019. Gareth will step down from the Board with immediate effect, and plans to remain with the Group until the end of 2020 in order to effect an orderly handover. Price Target Changed • Nov 17
Price target lowered to UK£0.009 Down from UK£0.09, the current price target is provided by 1 analyst. The new target price is 127% above the current share price of UK£0.004. As of last close, the stock is down 65% over the past year. Aankondiging • Aug 27
Tissue Regenix Group plc to Report First Half, 2020 Results on Sep 02, 2020 Tissue Regenix Group plc announced that they will report first half, 2020 results on Sep 02, 2020 Aankondiging • Aug 17
Tissue Regenix Group Announces Relocation of Manufacturing Facility Tissue Regenix Group announced the relocation of the company's UK head office and manufacturing facilities to Garforth, Leeds, in November 2020. The strategic decision to relocate the company's UK operations from nearby Swillington, Leeds, was made as part of the ongoing overhead cost saving initiatives being implemented by Tissue Regenix and is expected to reduce the Group's overhead spend by over £400,000 on an annualised basis from 2021. As part of the relocation programme, the Group will outsource elements of the production cycle relating to testing and packaging, but will retain its processing capabilities including the manufacturing of OrthoPure® XT.